Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program

Publisher： Karger

E-ISSN： 1423-0232|78|5-6|340-347

ISSN： 0030-2414

Source： Oncology, Vol.78, Iss.5-6, 2010-08, pp. : 340-347

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 204-209

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial

By  

Oncology, Vol. 88, Iss. 5, 2015-01 ,pp. : 273-280

Karger

Access to resources Recommend Favorite

Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 84, Iss. 2, 2012-11 ,pp. : 108-114

Karger

Access to resources Recommend Favorite

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 350-354

Karger

Access to resources Recommend Favorite

Downsizing a Thrombus of Advanced Renal Cell Carcinoma in a Presurgical Setting with Sorafenib

By  

Urologia Internationalis, Vol. 88, Iss. 2, 2011-12 ,pp. : 235-237

Karger

Access to resources Recommend Favorite